Treace Medical Concepts (TMCI) AI Stock Analysis

• Market Cap: $118.52M
• Dividend Yield: N/A
• Average Volume (3M): 918.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: 7.90%
• EPS Growth: 19.92%
• Country: US
• Employees: 477
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.15
• Shares Outstanding: 63,718,075
• 10 Day Avg. Volume: 1,009,218
• 30 Day Avg. Volume: 918,480
• PEG Ratio: -0.79
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 0.73
• P/FCF Ratio: -5.26
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 0.57
• Enterprise Value/Gross Profit: 0.72
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $3.56
• Price Target Upside: 91.53% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.85
• Revenue Forecast (FY): $210.29M

• Rating: 43 Neutral
• Price Target: $2.00 ▲(7.53% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

The score is primarily held back by weak financial performance (ongoing losses and negative free cash flow) and bearish technicals (below all key moving averages with negative MACD). The earnings outlook is mixed—management expects significantly lower cash usage and continued product/adoption progress, but 2026 guidance implies flat-to-declining revenue and continued adjusted EBITDA losses, limiting near-term conviction.

Positive Factors

High Gross Margins

Treace’s gross margins near 80% reflect high-margin proprietary implants and instrumentation. That per-procedure economics are structural — if procedure volumes recover and SG&A scales efficiently, gross profitability can translate into durable operating leverage and quicker path to sustained profitability.

Improved Leverage / Liquidity

The December secured financing and existing liquidity materially strengthen the balance sheet and provide non-dilutive capital for commercialization. Longer-term committed capacity reduces near-term refinancing risk and gives runway to invest in sales, training, and product launches without immediate dilution.

Broader Product Portfolio & Surgeon Base

Introducing three new systems and growing the active surgeon base expands Treace’s addressable cases and reduces reliance on a single procedure. A broader suite that aligns with surgeon preferences, plus recent senior commercial hires, supports sustainable market penetration and long-term share gains.

Negative Factors

Persistent Cash Burn

Despite margin strength, Treace remains cash negative with about -$29M free cash flow TTM and consistently negative operating cash flow. Continued reliance on external financing constrains strategic flexibility and increases execution risk unless cash generation turns positive sustainably.

Stalled Revenue Growth

Revenue has plateaued around the ~$210M level, with TTM contraction and only modest full-year guidance. A growth stall limits operating leverage and pressures margin expansion, making it harder to absorb fixed costs and achieve self-funded profitability without renewed, durable procedure demand.

Procedure Mix / Competitive Risk

Surgeon preference shifts toward minimally invasive osteotomies have reduced Lapiplasty volumes. This structural clinical preference change can depress ASPs and share unless new product iterations and training materially reverse adoption trends, posing durable demand and pricing headwinds.

Treace Medical Concepts Business Overview & Revenue Model

Company Description

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

How the Company Makes Money

TMCI generates revenue primarily through the sale of its orthopedic surgical products, particularly those related to the Lapiplasty® procedure. The company's revenue model is based on direct sales to hospitals and surgical centers, along with distribution through medical device wholesalers. Key revenue streams include product sales from its proprietary devices, instrumentation, and surgical kits. Additionally, TMCI may benefit from strategic partnerships with healthcare providers and distributors to expand its market reach. The company also invests in ongoing research and development to innovate and diversify its product offerings, which can lead to new revenue opportunities.

Treace Medical Concepts Financial Statement Overview

Summary

Strong gross margins (~80%) and sharply reduced debt support financial flexibility, but the core profile remains weak due to persistent operating losses (TTM operating margin ~-20%), deeply negative ROE (~-49%), and ongoing negative free cash flow (about -$29M TTM) despite improvement in cash burn.

Income Statement

Revenue scaled rapidly from 2020–2024, but TTM (Trailing-Twelve-Months) shows a slight contraction (down ~2.8%), suggesting growth has stalled near the ~$210M level. Profitability remains the key issue: despite consistently strong gross margins (~80%), operating results are materially negative (TTM operating margin around -20%) and losses persist, indicating the cost structure has not yet scaled with revenue.

Balance Sheet

Leverage has improved meaningfully: total debt dropped sharply from ~70M (2022–2024) to ~14M in TTM (Trailing-Twelve-Months), and the company maintains a solid equity base (~87M TTM). That said, returns remain deeply negative (TTM return on equity around -49%), reflecting ongoing losses and limiting the quality of the balance sheet despite reduced debt.

Cash Flow

Cash generation remains weak with negative operating cash flow across all periods, though TTM (Trailing-Twelve-Months) burn improved versus 2024 (about -16M vs. -37M). Free cash flow is still meaningfully negative (about -29M TTM), indicating the business continues to require funding; while free cash flow has improved year-over-year, the company has not yet demonstrated sustained self-funding operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	212.69M	209.36M	187.12M	141.84M	94.42M
Gross Profit	169.75M	168.26M	151.94M	114.31M	77.53M
EBITDA	-43.18M	-42.07M	-39.01M	-36.28M	-15.81M
Net Income	-59.00M	-55.74M	-49.53M	-42.81M	-20.55M
Balance Sheet
Total Assets	190.58M	217.09M	251.91M	159.02M	140.82M
Cash, Cash Equivalents and Short-Term Investments	48.37M	75.68M	123.20M	81.25M	105.83M
Total Debt	13.98M	69.65M	70.30M	68.59M	29.36M
Total Liabilities	103.25M	104.20M	113.97M	98.50M	47.75M
Stockholders Equity	87.33M	112.89M	137.94M	60.53M	93.07M
Cash Flow
Free Cash Flow	-29.49M	-48.76M	-46.03M	-45.49M	-19.90M
Operating Cash Flow	-15.97M	-37.17M	-34.58M	-30.65M	-17.19M
Investing Cash Flow	13.25M	35.38M	-81.30M	-76.52M	-2.71M
Financing Cash Flow	2.08M	160.00K	109.38M	20.81M	107.65M

Treace Medical Concepts Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TMCI, the sentiment is Negative. The current price of 1.86 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.37, and below the 200-day MA of 4.93, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 36.77 is Neutral, neither overbought nor oversold. The STOCH value of 66.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TMCI.

Treace Medical Concepts Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	64 Neutral	$726.66M	78.18	4.97%	―	1.58%	―
TCMD	61 Neutral	$657.24M	34.91	8.77%	―	9.28%	21.00%
SIBN	56 Neutral	$685.45M	-35.12	-12.91%	―	23.27%	43.90%
KIDS	55 Neutral	$480.73M	-11.34	-12.67%	―	19.90%	-57.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50 Neutral	$543.15M	-5.78	-24.60%	―	4.31%	3.26%
TMCI	43 Neutral	$118.52M	-1.99	-51.63%	―	7.90%	19.92%

Treace Medical Concepts Corporate Events

Treace Medical Issues Preliminary Q4 Results, Highlights Growth

On January 13, 2026, Treace Medical Concepts reported preliminary, unaudited results showing fourth-quarter 2025 revenue of $62.1 million to $62.5 million, representing about a 9% year-over-year decline, while full-year 2025 revenue rose modestly by roughly 2% to a range of $212.3 million to $212.7 million, in line with its prior guidance. The company added approximately 202 new active surgeons in 2025 and ended the year with about 3,337 active surgeons, a 6% increase that now represents roughly one-third of the estimated 10,000 U.S. bunion surgeons, with management highlighting mid–single-digit growth in procedure volumes driven by adoption of its 3D bunion technologies despite macroeconomic and product-mix headwinds, and noting that formal 2026 financial guidance will be issued with its fourth-quarter 2025 earnings release in February 2026; executives emphasized maintaining Treace’s leading bunion-market position, further expanding procedure penetration and surgeon base, and improving profitability for shareholders as they present these trends to investors at the J.P. Morgan Healthcare Conference on January 14, 2026.

The most recent analyst rating on (TMCI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.

Treace Medical Completes New Secured Loan Financing Deal

On December 17, 2025, Treace Medical Concepts entered into new five-year senior secured loan agreements with credit funds managed by SLR Capital Partners, establishing up to $175 million in total debt capacity through a $125 million term loan facility and a revolving credit facility that can reach $50 million, replacing prior credit lines with MidCap Financial Trust. The company drew $60 million at closing, used the proceeds to repay its $50 million term loan and $4 million outstanding under its former revolver while incurring $2.3 million in associated prepayment and exit fees, and emerged with approximately $165 million in total liquidity, although the new covenants restrict dividend payments and are secured by substantially all assets, including intellectual property. The financing, which carries SOFR-based interest rates with an initial 48-month interest-only period and potential extension, is intended to provide Treace with non-dilutive capital, enhance balance sheet strength and financial flexibility, and support its efforts to expand its market presence in bunion surgery. Separately, on December 16, 2025, the board appointed veteran healthcare executive and existing director John K. Bakewell as lead independent director, reinforcing governance with an experienced financial and medical device industry leader.

The most recent analyst rating on (TMCI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.